Abacus Wealth Partners LLC lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 36.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,023 shares of the company’s stock after buying an additional 1,885 shares during the quarter. Johnson & Johnson comprises approximately 0.2% of Abacus Wealth Partners LLC’s holdings, making the stock its 28th biggest position. Abacus Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,138,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in JNJ. Innealta Capital LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $44,000. MFA Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $43,000. Grayhawk Investment Strategies Inc. boosted its holdings in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the period. Finally, Fairfield Financial Advisors LTD acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $46,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
JNJ stock opened at $160.50 on Friday. The stock has a market cap of $386.27 billion, a price-to-earnings ratio of 10.01, a P/E/G ratio of 2.69 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a 50 day simple moving average of $162.61 and a 200 day simple moving average of $154.30. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.09%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on JNJ shares. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Friday, September 20th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.21.
Check Out Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- Most active stocks: Dollar volume vs share volume
- Beat the Volatility: Top 3 Low-Beta Stocks to Watch
- Insider Buying Explained: What Investors Need to Know
- Visa and Mastercard: Top Payment Stocks to Watch After Rate Cuts
- How to Choose Top Rated Stocks
- When Is the Best Time to Invest in Mutual Funds?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.